The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the ongoing evolution of the biotech sector's approach to rare diseases, Pharvaris announced that the U.S. FDA has accepted its New Drug Application (NDA) for deucrictibant IR. According to reports, the agency has set a PDUFA action date for April 23, 2027. This regulatory milestone marks a significant step for the company as it seeks to provide oral treatment options for acute Hereditary Angioedema (HAE) attacks.
Pharvaris aims to establish a vertically integrated franchise for HAE treatment by developing deucrictibant in two distinct formulations. Beyond the current NDA acceptance, the company is anticipating Phase 3 CHAPTER-3 data for its XR formulation in the third quarter of 2026. These clinical and regulatory efforts follow positive results from the RAPIDe-3 trial, which underpin the company's strategy to reshape the therapeutic landscape for HAE patients.
While current price levels for the instrument are unavailable at this time, market participants are focused on the upcoming clinical catalysts scheduled for 2026 ahead of the 2027 regulatory decision. In the broader macroeconomic environment, the Federal Reserve maintained interest rates at 3.75% as of July 29, 2026, a factor that remains critical for risk appetite within the capital-intensive biotechnology industry.